Trastuzumab, a well–established monoclonal antibody treatment for HER2+ breast cancer, binds to the extracellular component of the HER2 receptor, limiting HER2 cleavage and leading to inhibition of angiogenesis, and DNA damage repair [4]. This evidence concerns the gene ERBB2 and breast carcinoma.